IntraOp Announces First Randomized Phase II Selection Trial of FLASH Versus Conventional Radiotherapy for Patients with Localized Carcinomas
It marks the first time a randomized trial will compare FLASH radiotherapy* to conventional radiotherapy in treating nonmelanoma skin cancer (NMSC).
- It marks the first time a randomized trial will compare FLASH radiotherapy* to conventional radiotherapy in treating nonmelanoma skin cancer (NMSC).
- It is the second clinical human trial to use the IntraOp® Mobetron® electron-based linear accelerator (LINAC).
- “This feels like a breakthrough moment in our collective study of the role and effectiveness of FLASH radiotherapy as compared to standard of care radiotherapy.
- *Ultra-High Dose Rate (UHDR) functionality for FLASH Radiotherapy is for investigational use only and is not cleared for sale by the US FDA.